Innovation in the Biopharmaceutical R&D Process – Adapting to a Changing Environment

This backgrounder looks at the strategies and tactics biopharmaceutical companies have implemented to adapt to evolving trends in the research and development (R&D) process. While the last five years have been among the most productive in history for new drug approvals and innovation, this remarkable progress follows a decade of reduced productivity levels.

The Value of Innovation in Oncology - Recognizing Emerging Benefits Over Time Executive Summary

Biopharmaceutical Companies Driving Personalized Medicine

Research in Pennsylvania

Sens. Portman, Cornyn, et al letter

Morning Consult - PhRMA National Poll - 5.1.15

PhRMA ITC Testimony - April 23, 2015

Clinical Trials Awareness Week Toolkit

PhRMA Statement on First FDA Approval of A Biosimilar Product

PhRMA supports a science-based, transparent implementation of the BPCIA biosimilars pathway.

2005 - 2015: A Decade of Innovation In Rare Diseases

Pages

Subscribe to RSS - Innovation